Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
Stock Snapshot
With a market cap of 213.43B, Novo Nordisk(NVO) trades at $47.69. The stock has a price-to-earnings ratio of 14.09 and currently yields dividends of 2.5%.
On 2025-11-18, Novo Nordisk(NVO) stock moved within a range of $47.20 to $48.27. With shares now at $47.69, the stock is trading +1.0% above its intraday low and -1.2% below the session's peak.
Trading activity shows a volume of 14.64M, compared to an average daily volume of 24.2M.
Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $45.05.
Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $45.05.
NVO News
Novo Nordisk will cut the direct-to-consumer prices of Wegovy and Ozempic, bringing monthly costs for many cash-paying patients down to $349....
Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health, retaining the price target of $32.00. Meet Your ETF AI Analyst...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
Analyst ratings
59%
of 32 ratingsMore NVO News
Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of...
The stock of pharmaceutical company Eli Lilly (LLY) is down 1% on Nov. 17 after news broke that rival Novo Nordisk (NVO) has lowered the direct-to-consumer pric...
Newly installed Chairperson Lars Rebien Sorensen signaled a rapid shift in governance and strategic direction at Novo Nordisk A/S (NYSE:NVO) , saying he intends...
Novo Nordisk (NVO) undercut Eli Lilly (LLY) and the Trump administration on Monday, slashing the cash price of its drugs Wegovy and Ozempic to just $349 a month...
GoodRx (GDRX) announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telem...
Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor m...
Novo Nordisk and Eli Lilly both agreed to cut prices for their weight-loss drugs as part of deals with Trump. Hollie Adams/Reuters Novo Nordisk NOVO.B -1.43 %d...
